In the dynamic field of biotherapeutics, understanding and managing anti-drug antibodies (ADAs) is critical for the success of drug development programs. ADAs can potentially neutralize the efficacy of biotherapeutic drugs, making it essential to have robust testing methodologies in place from the preclinical to clinical stages. KCAS Bio is excited to invite you to view the webinar, “Navigating the Current Landscape of Anti-Drug Antibodies Testing: From Preclinical to the Clinical Stages,” hosted by Xtalks. This event provides valuable insights into ADA testing, led by two of our esteemed experts, Cheikh Kane and Dominic Warrino.

Meet the Experts

Cheikh Kane, PhD, Executive Director, Biopharma Services, KCAS Bio

Cheikh Kane brings over two decades of experience in bioanalytical and biomarker assay development to KCAS Bio. As the Executive Director of Biopharma Services, Kane leads a team focused on bioanalytical ligand binding assays (LBA) and cell-based neutralizing antibody assays (NAB) that support drug development for biologics. His extensive background spans both the biopharmaceutical industry and the CRO business, having previously held key positions at Nexelis US, Boehringer Ingelheim-US, and Charles River Laboratories in Canada. At KCAS Bio, Kane is instrumental in defining and implementing strategic initiatives that expand the company’s footprint in the bioanalytical and biomarkers fields. His experience includes supporting numerous programs for a variety of therapeutic modalities, making him a leading voice in the field.

Dominic Warrino, PhD, Senior Director of Scientific Services, KCAS Bio

Dominic Warrino is a Senior Director of Scientific Services at KCAS Bio, where he leads a team of scientific advisors who act as liaisons between clients and internal teams. His expertise lies in the development, validation, and application of bioanalytical methods for pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and biomarker analysis across all therapeutic modalities, including biopharmaceuticals, pharmaceuticals, gene therapies, and cell-based gene therapies. With 30 years of experience, Warrino has a deep understanding of various bioanalytical techniques, including ECL, ELISA, RIA, flow cytometry, and more. His previous roles at Viracor-IBT, Cytogen, Eligix, and Streck Laboratories have provided him with a wealth of knowledge that he now applies to drive innovation and excellence at KCAS Bio.

Webinar Highlights

During this informative webinar, Kane and Warrino will guide attendees through the latest trends and best practices in ADA testing. Their combined expertise will provide a comprehensive overview of ADA testing strategies, regulatory requirements, and real-world applications that are critical for ensuring the safety and efficacy of biotherapeutic drugs.

Key topics will include:

  • The Role of ADA Testing in Drug Development: How ADA testing impacts the safety and efficacy of biotherapeutics across various stages of development.
  • Innovations in ADA Testing: Cutting-edge methodologies and technologies that enhance the accuracy and reliability of ADA testing.
  • Navigating Regulatory Requirements: Insights into the current regulatory landscape and how to ensure compliance in ADA testing.
  • Case Studies: Real-world examples of successful ADA testing strategies.

Why You Should Participate

This webinar is an essential resource for professionals involved in drug discovery, clinical trials, regulatory affairs, and bioanalysis. Whether you’re looking to deepen your understanding of ADA testing or stay current with the latest industry practices, this session offers invaluable insights from two of KCAS Bio’s leading experts.

Complete the form below to gain access

Whether you’re new to ADA testing or looking to refine your knowledge, this webinar will equip you with the tools and insights needed to navigate the complex landscape of ADA testing.

We look forward to your participation and to helping you advance your ADA testing strategies in the ever-evolving world of biotherapeutics.

Don’t miss out—advance your expertise and support your drug development projects with the latest insights.